2 active not recruiting, 2 terminated, 1 completed. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 2, Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow ropidoxuridine: new trials by email Literature Review of ropidoxuridine trials Research Report on ropidoxuridine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter Ropidoxuridine - Glioblastoma, IDH-wildtype | Phase 2 | Terminated | Shuttle Pharmaceuticals, Inc. | 30 | 2024-09-02 | 2025-12-18 |
| Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer Capecitabine, Radiation Therapy, Ropidoxuridine - Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2021-03-17 | 2025-02-26 |
| Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 11 | 2017-05-08 | 2026-11-18 |
| Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2016-02-01 | 2026-11-18 |
| An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas IPdR - Neoplasms, Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 10 | 2010-10-26 | 2018-10-18 |
Rectal Neoplasms (2) · Brain Neoplasms (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Glioblastoma (1) · Hematologic Neoplasms (1) · Liver Neoplasms (1) · Lymphoma (1) · Neoplasms (1) · Stomach Neoplasms (1)
National Cancer Institute (NCI) (4) · Shuttle Pharmaceuticals, Inc. (1)
United States (5)
Charles Kunos (1) · Pranshu Mohindra (1) · Shivaani Kummar, M.D. (1) · Timothy J Kinsella (1)
UM1CA186644 (1), UM1CA186686 (1), UM1CA186691 (1), UM1CA186712 (1), UM1CA186716 (1)